Brokerages expect Omnicell, Inc. (NASDAQ:OMCL) to announce earnings of $0.41 per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Omnicell’s earnings, with estimates ranging from $0.40 to $0.41. Omnicell reported earnings per share of $0.29 in the same quarter last year, which would indicate a positive year over year growth rate of 41.4%. The business is expected to report its next quarterly earnings results on Thursday, April 25th.
On average, analysts expect that Omnicell will report full year earnings of $2.52 per share for the current financial year, with EPS estimates ranging from $2.48 to $2.55. For the next fiscal year, analysts expect that the business will post earnings of $2.86 per share, with EPS estimates ranging from $2.78 to $2.90. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Omnicell.
Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 7th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.54 by $0.16. The firm had revenue of $211.75 million for the quarter, compared to the consensus estimate of $215.41 million. Omnicell had a net margin of 4.79% and a return on equity of 9.31%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.55 earnings per share.
Several research analysts have recently weighed in on OMCL shares. BidaskClub raised shares of Omnicell from a “hold” rating to a “buy” rating in a report on Wednesday, February 13th. ValuEngine raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Zacks Investment Research cut shares of Omnicell from a “buy” rating to a “hold” rating in a report on Monday, December 31st. Dougherty & Co boosted their price objective on shares of Omnicell from $78.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, March 7th. Finally, Piper Jaffray Companies reissued a “neutral” rating and set a $70.00 price objective on shares of Omnicell in a report on Friday, February 8th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $76.56.
Shares of NASDAQ OMCL traded up $0.30 during midday trading on Wednesday, hitting $81.15. The stock had a trading volume of 11,837 shares, compared to its average volume of 333,678. The company has a market cap of $3.33 billion, a PE ratio of 53.04, a P/E/G ratio of 3.76 and a beta of 1.24. Omnicell has a 52 week low of $42.01 and a 52 week high of $86.87. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.45 and a current ratio of 1.94.
In other Omnicell news, Director Gary S. Petersmeyer sold 750 shares of the company’s stock in a transaction that occurred on Tuesday, February 12th. The shares were sold at an average price of $78.87, for a total transaction of $59,152.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joseph Brian Spears sold 9,346 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $85.10, for a total transaction of $795,344.60. The disclosure for this sale can be found here. Insiders have sold 89,674 shares of company stock valued at $7,294,010 over the last three months. 3.71% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Omnicell by 27.9% during the third quarter. Vanguard Group Inc. now owns 3,806,211 shares of the company’s stock valued at $273,665,000 after buying an additional 830,338 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in Omnicell during the fourth quarter valued at approximately $372,000. Teton Advisors Inc. increased its holdings in Omnicell by 1.6% during the fourth quarter. Teton Advisors Inc. now owns 63,677 shares of the company’s stock valued at $3,900,000 after buying an additional 1,000 shares during the last quarter. BlackRock Inc. increased its holdings in Omnicell by 5.9% during the third quarter. BlackRock Inc. now owns 5,903,099 shares of the company’s stock valued at $424,432,000 after buying an additional 327,747 shares during the last quarter. Finally, Comerica Bank increased its holdings in Omnicell by 1.2% during the fourth quarter. Comerica Bank now owns 74,551 shares of the company’s stock valued at $4,685,000 after buying an additional 866 shares during the last quarter. 97.63% of the stock is owned by institutional investors and hedge funds.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Further Reading: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.